Skip to main content
In stock | Immunotherapy (Investigational Checkpoint)

Etigilimab

Oncology Type Both (Solid & Hematologic)
Drug Class / Mechanism TIM-3 / LAG-3 / TIGIT Inhibitor
No Image
Description

Etigilimab is classified as a TIM-3 / LAG-3 / TIGIT Inhibitor, sourced for use within our Immunotherapy (Investigational Checkpoint) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic Category Immunotherapy (Investigational Checkpoint)
Oncology Type Both (Solid & Hematologic)

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3